
|Articles|February 14, 2019
TARGET PharmaSolutions Launches Real-World Observational Study
Advertisement
TARGET PharmaSolutions, Inc., a company focused on real-world evidence, launched its latest large-scale observational study, TARGET-DERM. The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema). and vitiligo (loss of skin pigment).
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
2
Is Artificial Intelligence Coming for Clinical Research?
3
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
4
FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA
5






.png)



.png)



.png)
.png)
